• 11 hours Is This The Big Biotech Bust?
  • 17 hours Funding Is The Biggest Hurdle For Clean Energy
  • 1 day Walmart Reaches Out To Chilean Government For Protection
  • 2 days The Most Exciting Gold Find Of The Decade
  • 2 days Mining Boom Sparks Deforestation Concerns
  • 2 days The Cannabis Culling Has Wall Street Disappointed
  • 3 days Vigilante Offers $100,000 Bounty To Hack Banks
  • 3 days The Dairy Industry Is Dying
  • 4 days The Most Impressive Electric Vehicle Of The Year
  • 5 days Gold Miners Are Having A Stellar Second Half
  • 6 days How 3D Printing Is Turning Each And Every Industry On Its Head
  • 6 days Is The $3.5 Trillion Healthcare Industry About To Get Much More Transparent?
  • 6 days Gamblers Are Betting Big On Trump’s Impeachment
  • 7 days Even Banks Can't Answer Aramco's Trillion Dollar Question
  • 7 days Will Bezos Buy The Seattle Seahawks?
  • 8 days 6 Tech Trends Transforming The Travel Industry
  • 8 days Ousted Uber CEO Cashes Out $500 Million In Stock
  • 9 days Trump Prepares For Another Key Tariff Decision
  • 9 days The Free Money Bubble Is About To Burst
  • 9 days The Crushing Reality Of Poverty In America
Vigilante Offers $100,000 Bounty To Hack Banks

Vigilante Offers $100,000 Bounty To Hack Banks

A well-known vigilante hacker offered…

Is This The Big Biotech Bust?

Is This The Big Biotech Bust?

Biotechs are a train wreck…

Tom Kool

Tom Kool

Writer, Safehaven.com

Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com and Safehaven.com

Contact Author

  1. Home
  2. News
  3. Breaking News

Anti-Aging Market To Hit $55 Billion

Anti-Aging

It’s not just you who’s aging. Our world is getting old. By next year, 55-year-olds will outnumber 5-year-olds. By 2050, the number of people aged 50 and older will rise to 3.2 billion--a twofold increase since 2015.

Baby Boomers, born between 1944 and 1964, are now desperately searching for the “fountain of youth”, and the market is finally responding.

The anti-aging market is believed to be one of the fastest-growing market segments in existence. Last year, the Global Anti-Aging Market was worth $42.5 billion, and estimates are that it will reach $55.03 billion by 2023.

Aside from the “traditional” anti-aging products, there has also been a dramatic rise in the number of companies offering various treatments and products of a more extreme nature. Few of them are approved by the Federal Drug Administration (FDA).

But the potentially most exciting part is this: Scientists now believe it may be possible to reverse a person's biological age with a combination of drugs and growth hormones. The prospects are still far away, but there has been enough movement to make the anti-aging market’s mouth water:

A small, one-year clinical trial published in the Aging Cell journal, has suggested for the first time that it might be possible to reverse the biological age.

In the trial, led by immunologist Gregory Fahy, the chief scientific officer and co-founder of Intervene Immune, nine participants aged 51 to 65 were given a combination of growth hormone and two types of diabetes medications during the study.  On average, their biological ages were reduced by an average of 2.5 years.  Related: Are Investors Being Lulled Into A False Sense Of Security?

The researchers spent a year running the Thymus Regeneration, Immunorestoration and Insulin Mitigation (TRIIM) trials.

Initially, the trial was meant to test whether a growth hormone and drug combination could be used safely in humans to restore thymic function lost due to aging.

Apparently, even the scientists who worked on the study were surprised by the much more dramatic results.

Geneticist Steve Horvath at the University of California, who conducted the study, told Nature magazine: "I'd expected to see slowing down of the clock, but not a reversal. That felt kind of futuristic."

Still, researchers caution that the findings are only preliminary because the trial was small and did not include a control arm. But there is no doubt that many companies will cling onto the trial results and various “miraculous” products will hit the market.

It’s happened before.

Earlier this year, the FDA issued a warning that plasma infusions from young people provide no proven clinical benefit against normal aging and a handful of illnesses, as promised by the companies selling it. They all were citing several studies claiming this to be true, despite the fact that tests were only conducted on mice. Nothing stopped the product from hitting the market because of the frenzy to reverse aging.   

Even though the FDA statement didn't call out any companies by name, it was clearly targeting the best-known among these—California-based Ambrosia Medical, which since 2017, has been selling its ‘anti-aging” treatment for $8,000 for one liter of blood and $12,000 for two

Following the agency’s warning, the company ceased patient treatments but others out there have not felt the need in this hungry market.

A company called Elysium Health is one. It’s managed to convince Nobel Prize winners to help sell its $50/month supplement promoting “longevity”.

And last year, a former Florida-based mortician and doctor announced the launch of a clinical trial giving participants blood infusions from young donors for a modest $285,000 “enrollment” fee. Related: Insurance Businesses Are Fleeing The UK In Droves

Even the big dogs are toying with the idea.

Google’s parent company, Alphabet, has invested heavily in its secretive anti-aging spinout called Calico.

Celularity, a biotech giant Celgene spinoff, raised $250 million last year to try to use postpartum placentas to delay the aging process.

But from the FDA’s perspective, this is the 21st-century snake oil—and none of it has been proven. We’ll see what it says when the latest journal study inching towards biological age reversal starts inspiring more marketers.

By Tom Kool for Safehaven.com

More Top Reads From Safehaven.com:

Back to homepage

Leave a comment

Leave a comment